Grupo Biotoscana Raises $417 Million in Oversubscribed Brazil IPO

Jul 21 2017

LONDON, United Kingdom—EW Healthcare Partners (“EWHP”), a global healthcare growth equity investor, announced that Grupo Biotoscana (“Biotoscana”), a Pan-Latin American specialty pharmaceutical company focused on oncology and critical care drugs, successfully completed an oversubscribed $417 million IPO on the Brazilian Stock Exchange on July 21, 2017.  The IPO was priced at R$26.50 per share and was more than five times oversubscribed.  Biotoscana is listed on Brazil’s B3 Exchange under the trading symbol “GBIO33”.  EWHP continues to hold significant shareholding in GBT and maintain its presence in the Board of Directors. 
EWHP, in collaboration with private equity firm Advent International, has played a key role in helping in-license new products for Biotoscana, and executed the strategic add-on acquisitions of United Medical in Brazil in January 2014, and Laboratorio LKM in Argentina in December 2015.  “Essex’s deep healthcare expertise, industry relationships and strategic insights are helping Biotoscana achieve its mission of being the high growth specialty pharma company in Latin America”, affirmed CEO Mariano Garcia-Valino. 

GBT has experienced significant growth and developed a state-of-the-art infrastructure for the Latin American region, including accomplishing exemplary sales, marketing, R&D, regulatory, access and manufacturing capabilities.  The company’s broad portfolio of over 150 molecules in in-licensed innovative products, and robust and broad pipeline of 30+ new products under negotiation to be signed during 2017/2018, have led the company to become the partner of choice for specialty products in Latin America. 

GBT today develops and markets branded specialty pharma products in all major Latin American markets, including Brazil, Argentina, Colombia, Bolivia, Chile, Ecuador, Mexico, Paraguay, Peru and Uruguay.  The company’s effective management team, combined with their robust reputation developed over decades, and its track record in the industry and the region provide a strong basis for continued growth, underlying Latin American market momentum as well as global specialty segment momentum.  Dr. Evis Hursever, who serves on behalf of EWHP on the Board of Directors for Biotoscana confirmed, “We are delighted with Biotoscana’s continued growth and strength, and we plan to fully support the company’s positive momentum and encourage the expansion of its portfolio and footprint in this niche market.” 

Further information regarding the company may be obtained at www.grupobiotoscana.com.